Royalty Pharma vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Royalty Pharma Plc (RPRX)

Q3 202629 Jun – 13 Aug 2026

▲4

Royalty Pharma Raises Guidance Again, Adds AstraZeneca Royalty

Q2 beat and second guidance raise Royalty Pharma beat expectations and raised its 2026 outlook for the second quarter in a row, now guiding to $3.4–3.5 billion in portfolio receipts. Strong sales of Tremfya, Voranigo, Emdeltra and Evrysdi drove the beat, signaling its royalty base keeps growing.
This is the core new fundamental driver of the period and directly lifts future earnings expectations.
New AstraZeneca cliramitug royalty deal Royalty Pharma is paying up to $425 million for a 3–4% royalty on AstraZeneca's cliramitug, a Phase 3 heart drug for ATTR-CM. With peak sales seen at $3–5 billion, this adds a potential $110–190 million in annual royalty revenue later this decade.
This is a fresh capital deployment that expands the royalty portfolio and future cash flow.
Lupus drug litifilimab nears key data Royalty Pharma co-developed litifilimab with Biogen, and Phase 3 enrollment is complete with topline results due in the second half of 2026. Positive data would validate another late-stage pipeline asset and support future royalty growth.
It highlights a near-term clinical catalyst that could add a new royalty stream.
Stock hits 52-week high on earnings momentum RPRX touched $60.44 as investors reacted to 13% growth in first-quarter royalty receipts and the raised full-year outlook. The stock has gained 56% over the past year, reflecting growing confidence in the royalty model.
It shows the market is rewarding the company's consistent execution, reinforcing the positive trend.

July 202629 Jun – 13 Aug 2026

▲4

Royalty Pharma Raises Guidance Again, Adds AstraZeneca Royalty

Q2 beat and second guidance raise Royalty Pharma beat expectations and raised its 2026 outlook for the second quarter in a row, now guiding to $3.4–3.5 billion in portfolio receipts. Strong sales of Tremfya, Voranigo, Emdeltra and Evrysdi drove the beat, signaling its royalty base keeps growing.
This is the core new fundamental driver of the period and directly lifts future earnings expectations.
New AstraZeneca cliramitug royalty deal Royalty Pharma is paying up to $425 million for a 3–4% royalty on AstraZeneca's cliramitug, a Phase 3 heart drug for ATTR-CM. With peak sales seen at $3–5 billion, this adds a potential $110–190 million in annual royalty revenue later this decade.
This is a fresh capital deployment that expands the royalty portfolio and future cash flow.
Lupus drug litifilimab nears key data Royalty Pharma co-developed litifilimab with Biogen, and Phase 3 enrollment is complete with topline results due in the second half of 2026. Positive data would validate another late-stage pipeline asset and support future royalty growth.
It highlights a near-term clinical catalyst that could add a new royalty stream.
Stock hits 52-week high on earnings momentum RPRX touched $60.44 as investors reacted to 13% growth in first-quarter royalty receipts and the raised full-year outlook. The stock has gained 56% over the past year, reflecting growing confidence in the royalty model.
It shows the market is rewarding the company's consistent execution, reinforcing the positive trend.

Latest29 Jun – 13 Aug 2026

▲4

Royalty Pharma Raises Guidance Again, Adds AstraZeneca Royalty

Q2 beat and second guidance raise Royalty Pharma beat expectations and raised its 2026 outlook for the second quarter in a row, now guiding to $3.4–3.5 billion in portfolio receipts. Strong sales of Tremfya, Voranigo, Emdeltra and Evrysdi drove the beat, signaling its royalty base keeps growing.
This is the core new fundamental driver of the period and directly lifts future earnings expectations.
New AstraZeneca cliramitug royalty deal Royalty Pharma is paying up to $425 million for a 3–4% royalty on AstraZeneca's cliramitug, a Phase 3 heart drug for ATTR-CM. With peak sales seen at $3–5 billion, this adds a potential $110–190 million in annual royalty revenue later this decade.
This is a fresh capital deployment that expands the royalty portfolio and future cash flow.
Lupus drug litifilimab nears key data Royalty Pharma co-developed litifilimab with Biogen, and Phase 3 enrollment is complete with topline results due in the second half of 2026. Positive data would validate another late-stage pipeline asset and support future royalty growth.
It highlights a near-term clinical catalyst that could add a new royalty stream.
Stock hits 52-week high on earnings momentum RPRX touched $60.44 as investors reacted to 13% growth in first-quarter royalty receipts and the raised full-year outlook. The stock has gained 56% over the past year, reflecting growing confidence in the royalty model.
It shows the market is rewarding the company's consistent execution, reinforcing the positive trend.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.